Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Maria Elisa Mancuso

IRCCS Humanitas Research Hospital

Italy

Research Interests

Explore related searches

Professors in Italy

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (11)

Rolf Ljung

Professor

Lund University Medical Faculty Foundation

SWEDEN

View details

Flora Peyvandi

Università degli Studi di Torino

ITALY

View details

Nathan Connell

Harvard University

UNITED STATES

View details

Mark Skinner

Assistant Professor (part-time)

McMaster University

CANADA

View details

Roberta Gualtierotti

Associate Professor

Università degli Studi di Torino

ITALY

View details

Cedric Hermans

Head Division of Haemostasis and Thrombosis

BELGIUM

View details

Bryce Kerlin

Professor

Ohio State University

UNITED STATES

View details

Miguel Escobar

Professor (Tenure)

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Kathelijn Fischer

Universitair Medisch Centrum Utrecht

NETHERLANDS

View details

Shawn Jobe

Associate Professor

Michigan State University

UNITED STATES

View details

Patrizio Pasqualetti

Professore Associato

Sapienza University of Rome

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Maria Elisa Mancuso

Research Interests

Explore related searches

Articles (20)

“Deconstructing the ISTH Hemophilia Guidelines for the clinician”: comment from Mancuso et al.

BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study

Extension Study With rVIII‐SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A

Hemostasis Laboratory Diagnostics in Newborns

Correction to: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review (Drugs in R&D, (2024), 24, 3, (359-381), 10.1007/s40268-024-00481-7)

Effect of DNA methylation on inhibitor development in people with hemophilia A treated with FVIII concentrates

Shaping individualized care for women with hemophilia A

Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life

Better Communication for Better Management of Persons with Hemophilia: Results from a Patients’-Clinicians’ Project to Address the New Therapeutic Landscape

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease

International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia—A Critical Appraisal

A post hoc analysis of PROTECT VIII kids assessing long-term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A

Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review

Effect of statin intake on FVIII levels and bleeding outcomes in hypercholesterolemic patients with hemophilia A

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Factor Replacement Treatment for Hemophilia A: Achievements and Perspectives

Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions

Joint health and pain in the changing hemophilia treatment landscape

Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII

Collaborators (11)

Rolf Ljung

Flora Peyvandi

Nathan Connell

Mark Skinner

Roberta Gualtierotti

Cedric Hermans

Bryce Kerlin

Miguel Escobar

Kathelijn Fischer

Shawn Jobe

Patrizio Pasqualetti

Make your next move.